Section Editor: Allison Osmond MD FRCPC
June 18, 2026
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder is the name for a group of related conditions in which T cells (a type of immune cell) carrying a protein called CD30 build up in the skin. These conditions lie on a spectrum ranging from very slow-growing, often self-healing lesions to localized lymphoma (a cancer of immune cells).
This article explains what this group of conditions is, how the different types are told apart, and how the findings in your pathology report guide the decisions you and your care team make together. The most important step after this diagnosis is determining exactly which type is present, because the types differ greatly in how they behave and how they are treated. Your report may use this umbrella term while additional tests are done to refine the diagnosis. Most of these conditions stay limited to the skin and have a good outlook.
What conditions are included in this group?
Several CD30-positive T-cell conditions belong to this spectrum:
- Lymphomatoid papulosis — A long-lasting condition with small, raised skin lesions that often heal on their own but tend to come back over months or years. Although the cells share features with lymphoma, they behave in a very slow, benign way and rarely progress.
- Primary cutaneous anaplastic large cell lymphoma — A localized lymphoma that usually appears as one or more larger red or purple skin tumors that may form an open sore. It usually stays in the skin and has an excellent outlook. See our article on primary cutaneous anaplastic large cell lymphoma.
- CD30-positive advanced mycosis fungoides — A skin lymphoma that usually begins as scaly patches and can develop thicker plaques or tumors over time; CD30 may appear as the disease advances. See our article on mycosis fungoides.
- Overlap cases — Some cases share features of lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, which can make the diagnosis more difficult and is one reason the clinical picture matters so much.
- Systemic anaplastic large cell lymphoma involving the skin — A lymphoma that started elsewhere in the body and spread to the skin. It can look very similar under the microscope, but it is a different disease, so it must be ruled out.
How is the diagnosis made?
The diagnosis is made after a sample of affected skin is removed in a biopsy and examined under the microscope by a pathologist. Determining the specific type relies on combining the clinical picture (how the lesions look and behave over time) with the microscopic features and additional tests. No single piece of information is enough on its own, which is why these are considered clinical and pathologic diagnoses.
Under the microscope, the types differ in cell size and arrangement. In lymphomatoid papulosis, the abnormal cells are small to medium-sized and scattered within an inflammatory background of normal immune cells, resulting in a patchy, less dense appearance. In primary cutaneous anaplastic large cell lymphoma, the cells are large and form dense sheets, with irregular nuclei, prominent nucleoli, and abundant cytoplasm, sometimes with an ulcer on the surface. In CD30-positive advanced mycosis fungoides, the cells are usually smaller, infiltrate the skin in bands, and often have folded, brain-like (cerebriform) nuclei. Systemic anaplastic large cell lymphoma involving the skin can resemble the primary cutaneous form, so the pathologist looks for evidence that the disease originated outside the skin, such as involvement of lymph nodes or internal organs.
Several additional tests help refine the diagnosis. Immunohistochemistry highlights proteins such as CD30, CD4, and CD8 to confirm the type of T cell involved. Fluorescence in situ hybridization (FISH) detects genetic rearrangements, such as changes in the DUSP22 gene, which can help classify the disease. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) look for genetic mutations and for a single dominant (clonal) population of T cells. Imaging and blood tests are also used to confirm whether the disease is limited to the skin.
Why does the specific type matter?
The specific type determines the outlook and the best treatment. For example:
- Lymphomatoid papulosis — Often resolves on its own or needs only minimal treatment.
- Primary cutaneous anaplastic large cell lymphoma — May be treated with surgery or radiation when localized, or with medication if widespread.
- Genetic findings — Changes such as a DUSP22 rearrangement can give additional information about how the disease is expected to behave.
What happens after this diagnosis?
Because these conditions differ so much, treatment depends on the specific type, which is why pinpointing it is the priority. Care is usually coordinated by a team that may include a dermatologist, a hematologist, or a medical oncologist, and a radiation oncologist. Lymphomatoid papulosis is often simply monitored, since lesions tend to heal on their own, with treatment used mainly to control symptoms. Localized primary cutaneous anaplastic large cell lymphoma is often treated with surgery or local radiation, and the CD30-targeted drug brentuximab vedotin may be an option for widespread or recurrent disease. CD30-positive mycosis fungoides is treated according to its stage. The detailed treatment options for each condition are described in the individual articles linked above, and regular skin examinations are an important part of follow-up for all of them.
Questions to ask your doctor
- Which specific type of CD30-positive disorder do I have?
- Is my disease limited to the skin, or has it spread?
- Were extra tests done (FISH for DUSP22, NGS, or clonality testing), and what did they show?
- Were my cells strongly CD30 positive?
- Is my condition the slow-growing type that may come and go on its own?
- What treatment is appropriate for my specific type?
- Could brentuximab vedotin be an option for me?
- What is my outlook?
- How often will I need follow-up and skin checks?
- Should I be seen at a center that specializes in cutaneous lymphoma?
Related articles
We are proud to partner with:
